$TEM

Fukushima Ryan sold $1.0M of TEM (indirect holdings)

Fukushima Ryan (CEO, Data) sold 20,000 indirectly-held shares of Tempus AI, Inc. (TEM) at $50.04 ($1.00M total) on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fukushima Ryan
Published Aug 11, 2026, 9:29 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 9:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TEM
Neutral
high confidence
Mentioned
$TEM
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The only new fact is the reported sale size, price, and that it was executed under a pre-arranged 10b5-1 plan; no new company performance or guidance is disclosed.

02

Market read

Traders may note the insider sale for sentiment, but it is unlikely to drive fundamentals without accompanying guidance, contract, or regulatory updates.

03

What to watch

The disclosure specifies indirect holdings and a pre-arranged plan, which reduces interpretability versus discretionary selling.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-11 after-hours; transaction dated 2026-08-07

Background

The article is a SEC Form 4 insider transaction report for Tempus AI, Inc.

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

Tempus AI CEO Fukushima Ryan sold 20,000 shares in an open-market transaction worth about $1.0M, under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operating, financial, or regulatory information.

Market effects

Minimal; insider sale does not change sector fundamentals or guidance for AI/healthcare tech peers.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can be purely mechanical and may not reflect bearish expectations; the market may overreact to the headline framing.

Key entities

  • Tempus AI, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Fukushima Ryan

    CEO, Data, reported an open-market sale of 20,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TEMMedAI 9/10

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Tempus AI (TEM) shares rose after Moderna and Merck reported positive Phase 3 trial results for a personalized cancer therapy, validating Personalis' sequencing technology. Tempus agreed to acquire Personalis for $1.5B, with the deal pending. Personalis' technology is distinct from the main target of the acquisition, NeXT Personal, a tumor-informed molecular residual disease test. Tempus reported 9,000 MRD tests in Q2, while Personalis generated $22.357M in revenue and delivered 10,384 clinical

$TEMMedAI 8/10

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

Tempus AI, Inc. (NASDAQ: TEM) received FDA clearance for its AI product, Tempus ECG-PH, designed to detect signs of pulmonary hypertension from standard ECGs. This is the third FDA-cleared cardiovascular device in Tempus' portfolio, aiming to help clinicians identify at-risk patients earlier. The product analyzes ECG data but is not intended for standalone diagnosis.

$TEMHighAI 8/10

Why Tempus AI Skyrocketed This Week

Tempus AI (TEM) shares rose 39.5% this week after Merck and Moderna reported positive Phase 3 trial data for their cancer vaccine, which uses technology from Personalis, a company Tempus is acquiring. Tempus's market cap is $13B, and its stock is still down about 10% over the past year. The acquisition is expected to close late 2024 or early 2027.

$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.